Ascletis Pharma (HKG:1672) said it completed the enrollment of participants in its oral acne medication Phase III clinical trials of ASC40, according to a Tuesday filing with the Hong Kong bourse.
A total of 480 participants with moderate to severe acne enrolled for once-a-day treatment.
The topline results from the study are expected by the second quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.